Mesa News Today | 2 Min News | The Daily News Now!
Early trial results for a personalized mRNA vaccine against pancreatic cancer are showing remarkable promise, with seven out of eight patients still alive six years after surgery. This vaccine, tailored from each patients own tumor, is being tested in a phase two trial to confirm its potential for wider use. Survivors and families are cautiously optimistic, hoping this breakthrough will rewrite the odds for pancreatic cancer patients.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/ad7bbd0728bff80e